Upgrade to SI Premium - Free Trial

Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition

April 6, 2026 1:10 PM
Baird analyst Brian Skorney reiterated an Outperform rating and $186.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented: "Incrementally ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles